[go: up one dir, main page]

MX2014014711A - Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar). - Google Patents

Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar).

Info

Publication number
MX2014014711A
MX2014014711A MX2014014711A MX2014014711A MX2014014711A MX 2014014711 A MX2014014711 A MX 2014014711A MX 2014014711 A MX2014014711 A MX 2014014711A MX 2014014711 A MX2014014711 A MX 2014014711A MX 2014014711 A MX2014014711 A MX 2014014711A
Authority
MX
Mexico
Prior art keywords
compounds
aryltriazole
lpar antagonists
lpar
antagonists
Prior art date
Application number
MX2014014711A
Other languages
English (en)
Inventor
Yimin Qian
Matthew Michael Hamilton
Achyutharao Sidduri
Stephen Deems Gabriel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014014711(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014014711A publication Critical patent/MX2014014711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I): así como sales de los mismos farmacéuticamente aceptables, en donde los sustituyentes son aquellos descritos en la especificación. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades y trastornos inflamatorios, tal como, por ejemplo, fibrosis pulmonar.
MX2014014711A 2012-06-20 2013-06-17 Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar). MX2014014711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20
PCT/EP2013/062463 WO2013189865A1 (en) 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
MX2014014711A true MX2014014711A (es) 2015-03-04

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014711A MX2014014711A (es) 2012-06-20 2013-06-17 Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar).

Country Status (22)

Country Link
US (1) US20150133512A1 (es)
EP (1) EP2864301A1 (es)
JP (1) JP2015520203A (es)
KR (1) KR20150011389A (es)
CN (1) CN104395299A (es)
AU (1) AU2013279513A1 (es)
BR (1) BR112014030674A2 (es)
CA (1) CA2869564A1 (es)
CL (1) CL2014003241A1 (es)
CO (1) CO7131357A2 (es)
EA (1) EA201492281A1 (es)
HK (1) HK1206339A1 (es)
IL (1) IL236087A0 (es)
IN (1) IN2014DN09352A (es)
MA (1) MA37762B1 (es)
MX (1) MX2014014711A (es)
PE (1) PE20142305A1 (es)
PH (1) PH12014502363A1 (es)
SG (1) SG11201407228PA (es)
UA (1) UA110310C2 (es)
WO (1) WO2013189865A1 (es)
ZA (1) ZA201408167B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US20140213538A1 (en) * 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
EP3728210A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
KR102698386B1 (ko) 2017-12-19 2024-08-22 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
KR102725744B1 (ko) 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
EP3728223B1 (en) 2017-12-19 2022-12-28 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
EP3728196B1 (en) 2017-12-19 2023-04-05 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
AU2018392325A1 (en) 2017-12-19 2020-07-30 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
ES2941774T3 (es) 2018-09-18 2023-05-25 Bristol Myers Squibb Co Acidos oxabiciclo como antagonistas de LPA
US12209072B2 (en) 2018-09-18 2025-01-28 Bristol-Myers Squibb Company Cyclopentyl acids as LPA antagonists
CN111434653A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4337641A1 (en) 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US12503454B2 (en) 2021-05-13 2025-12-23 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240115978A (ko) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
JP2014508111A (ja) * 2010-12-07 2014-04-03 アミラ ファーマシューティカルス，インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
US8975235B2 (en) * 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
MA37764A1 (fr) * 2012-06-20 2016-01-29 Hoffmann La Roche Composés n-alkyltriazole utilisés comme antagonistes de lpar

Also Published As

Publication number Publication date
BR112014030674A2 (pt) 2017-06-27
PH12014502363A1 (en) 2015-01-12
CA2869564A1 (en) 2013-12-27
EP2864301A1 (en) 2015-04-29
HK1206339A1 (en) 2016-01-08
EA201492281A1 (ru) 2015-04-30
US20150133512A1 (en) 2015-05-14
MA37762A1 (fr) 2017-07-31
ZA201408167B (en) 2015-12-23
PE20142305A1 (es) 2015-01-16
AU2013279513A1 (en) 2014-10-16
KR20150011389A (ko) 2015-01-30
IL236087A0 (en) 2015-02-01
UA110310C2 (uk) 2015-12-10
WO2013189865A1 (en) 2013-12-27
JP2015520203A (ja) 2015-07-16
CO7131357A2 (es) 2014-12-01
CL2014003241A1 (es) 2015-03-20
IN2014DN09352A (es) 2015-07-17
SG11201407228PA (en) 2014-12-30
MA37762B1 (fr) 2018-04-30
CN104395299A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
IN2014DN09434A (es)
IN2014MN02598A (es)
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX354102B (es) Derivados de bencimidazol-prolina.
IN2015DN01119A (es)
EA201591195A1 (ru) Новые хинолоновые производные
MX2016002794A (es) Compuestos antiproliferativos.
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
IN2014DN06869A (es)
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
UA117154C2 (uk) Антагоністи s1p3
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2015002755A3 (en) Compounds for the treatment of malaria
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
MY189372A (en) Indole derivatives
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
UA112586C2 (uk) Похідні бензімідазолпроліну